FDA
-
-
-
-
-
-
-
Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025
-
-
-
-
-
-
-
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
-
-
-
-
-
-
-
Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results
-
-
-
-
-
-
-
Design Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results
-
-
-
-
-
-
-
vTv Therapeutics (VTVT) Appoints Deepa Prasad as President and CEO
-
-
-
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

